肌层浸润性膀胱癌保留膀胱三联疗法后的长期结局:马萨诸塞州总医院经验的更新分析
该研究纳入1986至2013年在马萨诸塞州总医院按方案治疗的475例cT2-T4a肌层浸润性膀胱癌患者,采用经尿道膀胱肿瘤切除后同步放化疗。中位随访7.21年,5年与10年疾病特异性生存率分别为66%和59%,5年与10年总生存率分别为57%和39%,5年挽救性膀胱切除术风险为29%。
要点
- T2期、放化疗完全缓解与肿瘤相关原位癌是总生存和疾病特异性生存的显著预测因素。
- 1986-1995至2005-2013年间,完全缓解率从66%升至88%,5年疾病特异性生存率从60%升至84%。
- 同期5年挽救性根治性膀胱切除术风险从42%降至16%。
核心结论
- 接受三联疗法的患者完全缓解率和膀胱保留率高,疾病特异性生存率与 modern cystectomy series 相似。
- 当代结果尤其令人鼓舞,因此作者认为应将三联疗法作为特定患者的治疗选择进行讨论并提供。
研究设计与样本
- 研究纳入1986年至2013年间在马萨诸塞州总医院入组方案或按方案治疗的475例cT2-T4a肌层浸润性膀胱癌患者。
- 干预为经尿道膀胱肿瘤切除术后同步放疗和化疗。
- 对放化疗未达完全缓解或出现浸润性复发的患者,建议行挽救性根治性膀胱切除术。
- 采用Kaplan-Meier法计算疾病特异性生存和总生存。
主要发现
- 存活患者中位随访7.21年。
- 5年和10年疾病特异性生存率分别为66%和59%。
- 5年和10年总生存率分别为57%和39%。
- 5年挽救性膀胱切除术风险为29%。
- 多因素分析中,T2期疾病总生存风险比0.57(95%置信区间0.44-0.75),疾病特异性生存风险比0.51(95%置信区间0.36-0.73)。
临床怎么用
- 作者认为应将三联疗法作为特定肌层浸润性膀胱癌患者的治疗选择进行讨论并提供。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tri-modality therapy (TMT) is a recognized treatment strategy for selected patients with muscle-invasive bladder cancer (MIBC). OBJECTIVE: Report long-term outcomes of patients with MIBC treated by TMT. DESIGN, SETTING, AND PARTICIPANTS: Four hundred and seventy-five patients with cT2-T4a MIBC were enrolled on protocols or treated as per protocol at the Massachusetts General Hospital between 1986 and 2013. INTERVENTION: Patients underwent transurethral resection of bladder tumor followed by concurrent radiation and chemotherapy. Patients with less than a complete response (CR) to chemoradiation or with an invasive recurrence were recommended to undergo salvage radical cystectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease-specific survival (DSS) and overall survival (OS) were calculated using the Kaplan-Meier method. RESULTS AND LIMITATIONS: Median follow-up for surviving patients was 7.21 yr. Five- and 10-yr DSS rates were 66% and 59%, respectively. Five- and 10-yr OS rates were 57% and 39%, respectively. The risk of salvage cystectomy at 5 yr was 29%. In multivariate analyses, T2 disease (OS hazard ratio [HR]: 0.57, 95% confidence interval [CI]: 0.44-0.75, DSS HR: 0.51, 95% CI: 0.36-0.73), CR to chemoradiation (OS HR: 0.61, 95% CI: 0.46-0.81, DSS HR: 0.49, 95% CI: 0.34-0.71), and presence of tumor-associated carcinoma in situ (OS HR: 1.56, 95% CI: 1.17-2.08, DSS HR: 1.50, 95% CI: 1.03-2.17) were significant predictors for OS and DSS. When evaluating our cohort over treatment eras, rates of CR improved from 66% to 88% and 5-yr DSS improved from 60% to 84% during the eras of 1986-1995 to 2005-2013, while the 5-yr risk of salvage radical cystectomy rate decreased from 42% to 16%. CONCLUSIONS: These data demonstrate high rates of CR and bladder preservation in patients receiving TMT, and confirm DSS rates similar to modern cystectomy series. Contemporary results are particularly encouraging, and therefore TMT should be discussed and offered as a treatment option for selected patients. PATIENT SUMMARY: Tri-modality therapy is an alternative to radical cystectomy for patients with muscle-invasive bladder cancer, and is associated with comparable long-term survival and high rates of bladder preservation.
引用
- Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017. PMID: 28081860. doi:10.1016/j.eururo.2016.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。